In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
The Phase III ENGOT-OV44/First trial delivers a milestone in ovarian cancer research, suggesting immunotherapy could redefine standard of …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
FDA mandates clearer drug ads, Merck expands oncology portfolio, and political shifts raise questions about public health leadership.
Gilead’s twice-yearly injectable PrEP shows near-perfect efficacy, prompting global access initiatives and a rethinking of HIV prevention strategies.
A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
Already a subscriber? Log in